Nyembezi, AnamCassim, Nazneen2023-05-152026-06-102026-06-102022https://hdl.handle.net/10566/23557Master of Public Health - MPHHIV incidence amongst adolescent girls and young women (AGYW) is on the rise. Pre-exposure Prophylaxis (PrEP) trials prevent HIV amongst AGYW who are at heightened risk of acquiring HIV during trial participation until study exit. To prevent HIV amongst AGYW PrEP is required to be continued post PrEP trial participation. It is important to determine if AGYW continue with PrEP or whether they have discontinued PrEP after study exit and the reasons influencing post-trial PrEP continuation.enPublic healthHIVAdolescentsSexual and reproductive healthWorld Health Organization (WHO)University of the Western Cape